263 related articles for article (PubMed ID: 32763973)
1. Modulation of glycosyltransferase ST6Gal-I in gastric cancer-derived organoids disrupts homeostatic epithelial cell turnover.
Alexander KL; Serrano CA; Chakraborty A; Nearing M; Council LN; Riquelme A; Garrido M; Bellis SL; Smythies LE; Smith PD
J Biol Chem; 2020 Oct; 295(41):14153-14163. PubMed ID: 32763973
[TBL] [Abstract][Full Text] [Related]
2. The Tumor-Associated Glycosyltransferase ST6Gal-I Regulates Stem Cell Transcription Factors and Confers a Cancer Stem Cell Phenotype.
Schultz MJ; Holdbrooks AT; Chakraborty A; Grizzle WE; Landen CN; Buchsbaum DJ; Conner MG; Arend RC; Yoon KJ; Klug CA; Bullard DC; Kesterson RA; Oliver PG; O'Connor AK; Yoder BK; Bellis SL
Cancer Res; 2016 Jul; 76(13):3978-88. PubMed ID: 27216178
[TBL] [Abstract][Full Text] [Related]
3. ST6Gal-I sialyltransferase promotes tumor necrosis factor (TNF)-mediated cancer cell survival via sialylation of the TNF receptor 1 (TNFR1) death receptor.
Holdbrooks AT; Britain CM; Bellis SL
J Biol Chem; 2018 Feb; 293(5):1610-1622. PubMed ID: 29233887
[TBL] [Abstract][Full Text] [Related]
4. The ST6Gal-I sialyltransferase protects tumor cells against hypoxia by enhancing HIF-1α signaling.
Jones RB; Dorsett KA; Hjelmeland AB; Bellis SL
J Biol Chem; 2018 Apr; 293(15):5659-5667. PubMed ID: 29475939
[TBL] [Abstract][Full Text] [Related]
5. Sox2 promotes expression of the ST6Gal-I glycosyltransferase in ovarian cancer cells.
Dorsett KA; Jones RB; Ankenbauer KE; Hjelmeland AB; Bellis SL
J Ovarian Res; 2019 Oct; 12(1):93. PubMed ID: 31610800
[TBL] [Abstract][Full Text] [Related]
6. Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells.
Swindall AF; Bellis SL
J Biol Chem; 2011 Jul; 286(26):22982-90. PubMed ID: 21550977
[TBL] [Abstract][Full Text] [Related]
7. ST6Gal-I regulates macrophage apoptosis via α2-6 sialylation of the TNFR1 death receptor.
Liu Z; Swindall AF; Kesterson RA; Schoeb TR; Bullard DC; Bellis SL
J Biol Chem; 2011 Nov; 286(45):39654-62. PubMed ID: 21930713
[TBL] [Abstract][Full Text] [Related]
8. Modification of α2,6-sialylation mediates the invasiveness and tumorigenicity of non-small cell lung cancer cells in vitro and in vivo via Notch1/Hes1/MMPs pathway.
Yuan Q; Chen X; Han Y; Lei T; Wu Q; Yu X; Wang L; Fan Z; Wang S
Int J Cancer; 2018 Nov; 143(9):2319-2330. PubMed ID: 29981167
[TBL] [Abstract][Full Text] [Related]
9. The Glycosyltransferase ST6Gal-I Protects Tumor Cells against Serum Growth Factor Withdrawal by Enhancing Survival Signaling and Proliferative Potential.
Britain CM; Dorsett KA; Bellis SL
J Biol Chem; 2017 Mar; 292(11):4663-4673. PubMed ID: 28154177
[TBL] [Abstract][Full Text] [Related]
10. Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells.
Park JJ; Yi JY; Jin YB; Lee YJ; Lee JS; Lee YS; Ko YG; Lee M
Biochem Pharmacol; 2012 Apr; 83(7):849-57. PubMed ID: 22266356
[TBL] [Abstract][Full Text] [Related]
11. Regulation of inflammatory signaling by the ST6Gal-I sialyltransferase.
Holdbrooks AT; Ankenbauer KE; Hwang J; Bellis SL
PLoS One; 2020; 15(11):e0241850. PubMed ID: 33166339
[TBL] [Abstract][Full Text] [Related]
12. Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death.
Britain CM; Holdbrooks AT; Anderson JC; Willey CD; Bellis SL
J Ovarian Res; 2018 Feb; 11(1):12. PubMed ID: 29402301
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of sialyltransferases ST6GAL-I and ST3GAL-III in gastric cancer.
Gretschel S; Haensch W; Schlag PM; Kemmner W
Oncology; 2003; 65(2):139-45. PubMed ID: 12931020
[TBL] [Abstract][Full Text] [Related]
14. ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines.
Swindall AF; Londoño-Joshi AI; Schultz MJ; Fineberg N; Buchsbaum DJ; Bellis SL
Cancer Res; 2013 Apr; 73(7):2368-78. PubMed ID: 23358684
[TBL] [Abstract][Full Text] [Related]
15. Expression patterns of α2,3-sialyltransferase I and α2,6-sialyltransferase I in human cutaneous epithelial lesions.
Ferreira SA; Vasconcelos JL; Silva RC; Cavalcanti CL; Bezerra CL; Rêgo MJ; Beltrão EI
Eur J Histochem; 2013 Feb; 57(1):e7. PubMed ID: 23549466
[TBL] [Abstract][Full Text] [Related]
16. Increasing HER2 α2,6 sialylation facilitates gastric cancer progression and resistance via the Akt and ERK pathways.
Liu N; Zhu M; Linhai Y; Song Y; Gui X; Tan G; Li J; Liu Y; Deng Z; Chen X; Wang J; Jia L; He X; Wang X; Lin S
Oncol Rep; 2018 Nov; 40(5):2997-3005. PubMed ID: 30226606
[TBL] [Abstract][Full Text] [Related]
17. Expression of beta-galactoside alpha2,6 sialyltransferase and of alpha2,6-sialylated glycoconjugates in normal human liver, hepatocarcinoma, and cirrhosis.
Dall'Olio F; Chiricolo M; D'Errico A; Gruppioni E; Altimari A; Fiorentino M; Grigioni WF
Glycobiology; 2004 Jan; 14(1):39-49. PubMed ID: 14514712
[TBL] [Abstract][Full Text] [Related]
18. Sialyltransferase ST6GAL-1 mediates resistance to chemoradiation in rectal cancer.
Smithson M; Irwin R; Williams G; Alexander KL; Smythies LE; Nearing M; McLeod MC; Al Diffalha S; Bellis SL; Hardiman KM
J Biol Chem; 2022 Mar; 298(3):101594. PubMed ID: 35041825
[TBL] [Abstract][Full Text] [Related]
19. Glycosyltransferase ST6Gal-I promotes the epithelial to mesenchymal transition in pancreatic cancer cells.
Britain CM; Bhalerao N; Silva AD; Chakraborty A; Buchsbaum DJ; Crowley MR; Crossman DK; Edwards YJK; Bellis SL
J Biol Chem; 2021; 296():100034. PubMed ID: 33148698
[TBL] [Abstract][Full Text] [Related]
20. α2,6-Sialylation promotes immune escape in hepatocarcinoma cells by regulating T cell functions and CD147/MMP signaling.
Wang L; Li S; Yu X; Han Y; Wu Y; Wang S; Chen X; Zhang J; Wang S
J Physiol Biochem; 2019 Jun; 75(2):199-207. PubMed ID: 30972697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
